Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[High dose rate brachytherapy in prostate cancer in Norway].
Raabe NK, Lilleby W, Tafjord G, Aström L. Raabe NK, et al. Among authors: astrom l. Tidsskr Nor Laegeforen. 2008 May 29;128(11):1275-8. Tidsskr Nor Laegeforen. 2008. PMID: 18511969 Free article. Norwegian.
The association between age and long-term quality of life after curative treatment for prostate cancer: a cross-sectional study.
Sletten R, Berger Christiansen O, Oldervoll LM, Åstrøm L, Kjesbu Skjellegrind H, Šaltytė Benth J, Kirkevold Ø, Bergh S, Grønberg BH, Rostoft S, Bye A, Mork PJ, Slaaen M. Sletten R, et al. Among authors: astrom l. Scand J Urol. 2024 Feb 20;59:31-38. doi: 10.2340/sju.v59.18616. Scand J Urol. 2024. PMID: 38379397 Free article.
Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study.
Pettersson A, Alm D, Garmo H, Hjelm Eriksson M, Castellanos E, Åström L, Kindblom J, Widmark A, Gunnlaugsson A, Franck Lissbrant I, Nilsson P, Stattin P. Pettersson A, et al. Among authors: astrom l. JNCI Cancer Spectr. 2020 Feb 14;4(2):pkaa006. doi: 10.1093/jncics/pkaa006. eCollection 2020 Apr. JNCI Cancer Spectr. 2020. PMID: 32373776 Free PMC article.
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Fransson AS, Leskinen MJ, Zeke M, Huttunen T, Ginman C; Investigators of the Scandinavian Prostate Cancer Study No. 13. Kellokumpu-Lehtinen PL, et al. Among authors: astrom l. Eur Urol. 2019 Dec;76(6):823-830. doi: 10.1016/j.eururo.2019.08.010. Epub 2019 Aug 20. Eur Urol. 2019. PMID: 31443961 Clinical Trial.
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Merseburger AS, Attard G, Åström L, Matveev VB, Bracarda S, Esen A, Feyerabend S, Senkus E, López-Brea Piqueras M, Boysen G, Gourgioti G, Martins K, Chowdhury S. Merseburger AS, et al. Among authors: astrom l. Lancet Oncol. 2022 Nov;23(11):1398-1408. doi: 10.1016/S1470-2045(22)00560-5. Epub 2022 Oct 18. Lancet Oncol. 2022. PMID: 36265504 Clinical Trial.
27 results